Effect of T-Type Selective Calcium Antagonist on Renal Microcirculation: Studies in the Isolated Perfused Hydronephrotic Kidney

Although calcium antagonists exert preferential vasodilation of renal afferent arterioles, we have recently demonstrated that nilvadipine and efonidipine, possessing both L-type and T-type calcium channel blocking action, reverse the angiotensin (Ang) II–induced afferent and efferent arteriolar constriction. In the present study, we investigated the role of T-type calcium channels in mediating the Ang II–induced efferent arteriolar tone using the selective T-type calcium channel blocker mibefradil. Isolated perfused hydronephrotic rat kidneys were used for direct visualization of renal microcirculation. Administration of Ang II (0.3 nmol/L) caused marked constriction of afferent (from 13.5±0.6 to 9.2±0.6 &mgr;m, P <0.01, n=6) and efferent (from 11.5±1.0 to 7.4±0.7 &mgr;m, P <0.01, n=5) arterioles. Mibefradil (1 &mgr;mol/L) dilated both vessels, with 82±11% and 72±7% reversal of afferent and efferent arterioles, respectively. Similarly, nickel chloride (100 &mgr;mol/L) caused dilation of both arterioles, similar in magnitude in afferent (68±10%, n=7) and efferent (80±7%, n=7) arterioles. To eliminate the possibility that the mibefradil-induced dilation was mediated by L-type channel blockade, mibefradil was administered in the presence of nifedipine (1 &mgr;mol/L). Thus, nifedipine caused modest efferent arteriolar dilation (30±6% reversal, n=9), and subsequent addition of mibefradil elicited further dilation of this vessel (80±4%, P <0.01 versus nifedipine). Furthermore, mibefradil reversed the Ang II–induced efferent arteriolar constriction even in the presence of nifedipine and phentolamine. These findings demonstrate that T-type calcium antagonists markedly dilate the Ang II–induced efferent arteriolar constriction, but the action is not mediated by inhibition of catecholamine release. This potent activity would contribute to the efferent arteriolar response to nilvadipine and efonidipine and may offer benefit in light of glomerular hemodynamics.

[1]  Haruko Masumiya,et al.  Inhibition of T-Type and L-Type Ca2+ Currents by Aranidipine, a Novel Dihydropyridine Ca2+ Antagonist , 2000, Pharmacology.

[2]  T. Saruta,et al.  Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection. , 2000, Journal of cardiovascular pharmacology.

[3]  G. Molderings,et al.  N-Type calcium channels control sympathetic neurotransmission in human heart atrium. , 2000, Circulation.

[4]  T. Saruta,et al.  Role of protein kinase C in angiotensin II-induced constriction of renal microvessels. , 2000, Kidney international.

[5]  J. Ménard,et al.  Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. , 1999, Hypertension.

[6]  T. Olsson Activity in the Hypothalamic-Pituitary- Adrenal Axis and Delirium , 1999, Dementia and Geriatric Cognitive Disorders.

[7]  E. Frohlich,et al.  Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. , 1999, Hypertension.

[8]  T. Saruta,et al.  Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. , 1999, Journal of cardiovascular pharmacology.

[9]  N. Akaike,et al.  Effect of nilvadipine on the voltage-dependent Ca2+ channels in rat hippocampal CA1 pyramidal neurons , 1998, Brain Research.

[10]  H. Masumiya,et al.  Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. , 1998, European journal of pharmacology.

[11]  F. Werf,et al.  T‐type Ca2+ current as a trigger for Ca2+ release from the sarcoplasmic reticulum in guinea‐pig ventricular myocytes , 1998, The Journal of physiology.

[12]  T. Saruta,et al.  Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. , 1998, Clinical and experimental hypertension.

[13]  A. Dendorfer,et al.  Interactions between the renin-angiotensin system (RAS) and the sympathetic system , 1998, Basic Research in Cardiology.

[14]  T. Saruta,et al.  Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II. , 1997, The Journal of clinical investigation.

[15]  K. Abe,et al.  Diverse effects of calcium antagonists on glomerular hemodynamics. , 1996, Kidney international. Supplement.

[16]  K. Hermsmeyer,et al.  Protein kinase C mechanism enhances vascular muscle relaxation by the Ca2+ antagonist, Ro 40-5967. , 1996, Journal of vascular research.

[17]  T. Saruta,et al.  Disparate effects of calcium antagonists on renal microcirculation. , 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

[18]  R. Loutzenhiser,et al.  Divergent mechanisms of ATP-sensitive K+ channel-induced vasodilation in renal afferent and efferent arterioles. Evidence of L-type Ca2+ channel-dependent and -independent actions of pinacidil. , 1995, Circulation research.

[19]  R. Tsien,et al.  Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). , 1995, Molecular pharmacology.

[20]  F. Bühler,et al.  Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Mishra,et al.  Selective inhibition of T-type Ca2+ channels by Ro 40-5967. , 1994, Circulation research.

[22]  Y. Furuichi,et al.  Effect of Nilvadipine on the Development of Neurological Deficits in Stroke‐Prone Spontaneously Hypertensive Rats , 1994, Stroke.

[23]  P. Carmines,et al.  Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. , 1993, The American journal of physiology.

[24]  F. Marumo,et al.  Endothelin-1 enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes. , 1992, Circulation research.

[25]  M. Epstein Calcium Antagonists in Clinical Medicine , 1992 .

[26]  S. Tanaka,et al.  Effects of NZ‐105, a New Calcium Antagonist, on Renal Function in Anesthetized Spontaneously Hypertensive Rats , 1992, Journal of cardiovascular pharmacology.

[27]  M. Epstein,et al.  Pressure-Induced Vasoconstriction of Renal Microvessels in Normotensive and Hypertensive Rats: Studies in the Isolated Perfused Hydronephrotic Kidney , 1989, Circulation research.

[28]  M. Epstein,et al.  Effects of amlodipine on renal hemodynamics. , 1989, The American journal of cardiology.

[29]  M. Epstein,et al.  Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. , 1989, The American journal of physiology.

[30]  L. Navar,et al.  Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. , 1989, The American journal of physiology.

[31]  M. Epstein,et al.  Renal hemodynamic effects of calcium antagonists. , 1987, American Journal of Cardiology.

[32]  M. Epstein,et al.  Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. , 1988, The Journal of pharmacology and experimental therapeutics.

[33]  M. Steinhausen,et al.  Vasomotion and Vasoconstriction Induced by a Ca++-Agonist in the Split Hydronephrotic Kidney , 1988 .

[34]  M. Epstein,et al.  Renal hemodynamic effects of calcium antagonists. , 1987, Journal of cardiovascular pharmacology.

[35]  J. Fleming,et al.  Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. , 1987, The American journal of physiology.

[36]  R. Loutzenhiser,et al.  Characterization of the Renin-Angiotensin System in the Isolated Perfused Rat Kidney , 1979 .

[37]  J. Grosswendt,et al.  [Effect of BAY a 1040 on renal function in hypertension]. , 1972, Arzneimittel-Forschung.